Elsevier

The Lancet

Volume 339, Issue 8790, 15 February 1992, Pages 412-414
The Lancet

VIEWPOINT
Breast cancer treatment and natural history: new insights from results of screening

https://doi.org/10.1016/0140-6736(92)90090-PGet rights and content

First page preview

First page preview
Click to open first page preview

References (15)

  • B. Fisher et al.

    Significance of ipsilateral breast tumour recurrence after lumpectomy

    Lancet

    (1991)
  • L. Tabár et al.

    Reduction in mortality from breast cancer after mass screening with mammography

    Lancet

    (1985)
  • B. Fisher

    Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture

    Cancer Res

    (1980)
  • Er Fisher

    Pathobiologic considerations in the treatment of breast cancer

  • Sw Duffy et al.

    Breast screening, prognostic factors and survival-results from the Swedish two-county study

    Br J Cancer

    (1991)
  • L. Tabár, G. Fagerberg, Sw Duffy, et al., Update of the Swedish two-county programme of mammographic screening for...
  • L. Tabár et al.

    The Swedish two-county trial of mammographic screening for breast cancer: recent results and calculation of benefit

    J Epidemiol Commun Health

    (1989)
There are more references available in the full text version of this article.

Cited by (161)

  • Early stage triple negative breast cancer: Management and future directions

    2020, Seminars in Oncology
    Citation Excerpt :

    Taken altogether, these data have established anthracycline and taxane based chemotherapy as standard of care in TNBC patients. For patients with small TN tumors (≤1 cm), observation or TC chemotherapy alone can be considered given the overall good prognosis and low risk of recurrence with very early stage disease [41-48]. Preclinical and clinical studies have suggested increased sensitivity to DNA-damaging agents such as platinum drugs in TNBC due to intrinsic defects in DNA repair mechanisms.

  • Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?

    2018, Surgical Oncology Clinics of North America
    Citation Excerpt :

    Other approaches, such as genomically directed therapy (NCT02101385), immunomodulatory agents (NCT02954874), and vaccine strategies (NCT02427581), are being assessed in clinical trials in patients with residual TNBC after neoadjuvant chemotherapy. Patients with breast cancer who have T1a,b (≤1-cm) node-negative tumors generally have an excellent prognosis, with BCSS at 10 years exceeding 95%.62,63 Outcomes for these patients vary, however, by biologic subtype.64–69

  • Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study

    2017, European Journal of Cancer
    Citation Excerpt :

    Generalised mammographic screening has led to increase in the proportion of small breast tumours detection (invasive tumours measuring <2 cm or in situ carcinomas) from 36% to 68% [3,4]. Patients with T1a (≤5 mm) or T1b (>0.5–≤1 cm) node-negative tumours, generally have an excellent prognosis, with BC-specific survival at 10 years exceeding 95% [5,6]. However, outcomes for these patients may vary by tumour biological subtype [7,8].

  • Management strategy of early-stage breast cancer patients with a positive sentinel lymph node: With or without axillary lymph node dissection

    2011, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    Axillary lymph node dissection (ALND) was a part of the standard approach to breast cancer surgery during the last century [2]. Due to the popularization of screening policies and improvements in diagnostic methods, the incidence of node-involved disease is decreasing [3–5]. Over the last 20 years, sentinel lymph node biopsy (SLNB), defined as removal of the lymph node that first receives the lymphatic flow from the area of the primary tumor [6], was introduced and widely adopted as an alternative procedure to ALND for node staging [7,8].

View all citing articles on Scopus
View full text